# Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus

> **NCT03961828** · PHASE4 · COMPLETED · sponsor: **Tanta University** · enrollment: 50 (actual)

## Conditions studied

- Beta-Thalassemia
- Hepatitis C

## Interventions

- **DRUG:** Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]

## Key facts

- **NCT ID:** NCT03961828
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-01
- **Primary completion:** 2018-12-31
- **Final completion:** 2019-03-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03961828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03961828, "Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03961828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*